Today’s essential intelligence on markets, energy, AI and geopolitics.
Key takeaways:
• Key Emerging Themes
• Economic Pressures and Inflation
• Strategic Corporate Investments and Mergers
• Artificial Intelligence Development and Governance
J&J and Lilly buy biotech pipelines, with prices that depend on results
Johnson & Johnson (J&J), the US healthcare group, agreed on 16 November to buy the eye-disease biotech Ollin Biosciences for up to $3. UK to make larger banks keep in-person banking open
The UK government is set to require larger current account providers to “ensure reasonable access to essential in-person banking services”, limiting banks’ retreat from the high street, according to the FT on 16 November 2026.
Read the full newsletter: https://thegist.online/2026-11-16-jj-will-pay-up-to-33bn-for-ollin-en/
Subscribe free: https://thegist.online/subscribe-to-the-gist/?utm_source=podcast-en&utm_medium=show_notes
Transcript
JOHN: Welcome to The Gist. I’m John.
MARY: And I’m Mary. It is Monday, November 16th, 2026. Let’s get you up to speed.
JOHN: Let’s start with The Gist View. Today, we are looking at how big pharma actually builds its medicine cabinets.
MARY: Right. Johnson & Johnson just agreed to buy an eye-disease biotech company called Ollin Biosciences. The price tag? Up to 3.3 billion dollars.
JOHN: Notice those two words: “up to.” Eli Lilly just did the same thing. They are buying Calytrix Bio for up to 1.5 billion dollars. That adds to the 32 billion dollars Lilly has spent on acquisitions this year alone.
MARY: So, who really benefits here? Big pharma companies like J&J and Lilly are letting smaller startups take all the risk. They are not building these drugs from scratch. They are buying pipelines early. But they only pay top dollar if the drugs actually hit their clinical milestones.
JOHN: Think of it like buying a winning lottery ticket, but you only pay the full price if the numbers hit. If the drug fails trials, the startup founders and their venture capital backers take the financial hit. The big buyer just walks away, protecting its cash.
MARY: Exactly. And the venture investors are perfectly fine with this setup. Their incentive isn’t to run a massive company for ten years. They make their money by getting a drug just far enough along to sell it to a giant like J&J. That is their exit strategy.
JOHN: Plus, doing twenty small deals instead of one massive merger keeps the regulators happy. It avoids antitrust alarms. Calling this a market distortion misses the point. It is really just extreme specialization. Startups invent. Big pharma scales.
MARY: Moving to the Global Overview. The Nasdaq 100 took a hit this afternoon.
JOHN: That is the major index tracking the hundred largest non-financial tech companies in the US. It is the ultimate gauge of how investors value tech. And today, it dropped more than 2 percent.
MARY: The Financial Times is blaming the drop on “Nvidia fallout.” We need to watch this closely. Anthropic, the AI giant, is planning to price its initial public offering this Wednesday. A shaky tech market is not the welcome mat they want for a massive stock debut.
JOHN: Shifting to global trade. JD Sports is a massive athletic apparel retailer. Their CEO, Regis Schultz, says US shoppers are staying remarkably resilient.
MARY: But what about the new US tariffs? Schultz says JD’s stores aren’t really feeling the squeeze. Why? Because the brands they stock are eating the extra costs. The big clothing and shoe brands desperately want to keep their shelf space. So, they are absorbing the tax hit instead of passing it to shoppers.
JOHN: That is a classic power dynamic. The retailer holds the keys to the customer. So, the supplier pays the toll.
MARY: Meanwhile in Ottawa, Tiff Macklem is stepping down as governor of the Bank of Canada this coming June.
JOHN: The timing is critical. His successor takes over right as Canada tries to reduce its massive economic dependence on US trade. That will be a very difficult tightrope to walk.
MARY: Let’s bring it back home for the European Perspective. Here in Germany, Tesla is doubling down on automation.
JOHN: According to the broadcaster ZDF, Tesla plans to pour about 3 billion euros into its Grünheide plant near Berlin. They want a brand new facility to pump out up to one million Cybercabs.
MARY: Those are Tesla’s fully driverless robotaxis. Construction starts early next year, with production aimed at 2029. It is a massive influx of capital for the Brandenburg region, and the local government is thrilled.
JOHN: But doing business in Germany right now isn’t cheap. The ifo institute just released its price-expectations index. That metric tracks exactly how many German companies plan to raise their prices.
MARY: And that number is climbing fast. It jumped to 25.9 in October.
JOHN: The main culprit is energy. Crude oil and gas prices hit their highest levels since 2022 late last month. German businesses are being squeezed, and they are passing those costs straight to the consumer. Forecasters expect inflation to cross 3 percent very soon.
MARY: Finally, looking at the UK. The government is stepping in to stop the death of the high street bank branch.
JOHN: The Financial Times reports that larger banks will soon be legally required to keep essential, in-person banking services open.
MARY: Let’s look at the resource flows here. This rule is a huge win for elderly, rural, and cash-heavy customers who rely on a physical counter. The cost of keeping those branches open gets spread across all of the bank’s account holders. But the rule only applies to the big banks.
JOHN: Exactly. It creates a fascinating threshold. Smaller digital banks can avoid these heavy real estate costs. But if they grow too big, they trip the wire and suddenly have to pay for physical branch services. It is a hidden tax on growth that ironically protects the big, established banks from new competition.
MARY: So, what’s the temperature today? We are looking at a global economy where risk is carefully outsourced. From pharma giants making startups carry trial risks, to retailers making brands eat tariff costs, the biggest players are using their leverage to shield their margins. And as Europe wrestles with rising energy bills, the push for massive scale and automation, like Tesla’s robotaxis, is only accelerating.
JOHN: That is the big picture for today. If you enjoyed today’s breakdown and want to stay ahead of the curve, we’d love for you to get The Gist for free in your inbox every morning.
MARY: It’s the perfect companion to this podcast. Just tap the subscribe link right there in the show notes. Thanks for listening, and we’ll catch you tomorrow.
The Gist is an independent daily digest: AI-curated, human-directed, unapologetically liberal (how it’s made). Hundreds of sources, only what matters. Subscribe free or listen to the podcast.
